Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sionna Therapeutics, Inc.SION · Entity 5996 | Chief Business Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sionna Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.21 · Expires 2036-01-01 | Direct | 139,340 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 139,340 · Balance 139,340 F1: The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:14 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 139,340 | $0.00 Strike: $39.21 | $0.00 |
DisclosureSEC source: 0002085679-26-000002 · edgardoc.xml · derivative · entry 1 Beer Caroline Stark · CIK 0002085679 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,340 Underlying: Common Stock · 139,340 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares underlying this option vest in forty-eight equal monthly installments following January 2, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:14 UTC | Sionna Therapeutics, Inc. SION · Entity 5996 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 255,000 | $0.00 Strike: $28.47 | $0.00 |
DisclosureSEC source: 0002085679-25-000004 · edgardoc.xml · derivative · entry 1 Beer Caroline Stark · CIK 0002085679 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,000 Underlying: Common Stock · 255,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest on September 8, 2026, with the remainder vesting in thirty-six equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.